Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma

  • Technology appraisal guidance
  • TA268
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Dickson R, Boland A, Bagust A et al. Ipilimumab for previously treated unresectable malignant melanoma: a single technology appraisal (August, 2011)

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Bristol Myers-Squibb Pharmaceuticals

II Professional/specialist and patient/carer groups:

  • British Association of Dermatologists

  • Factor 50

  • Macmillan Cancer Support

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • Skin Care Campaign

III Other consultees:

  • Department of Health

  • Welsh Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Health Care Improvement Scotland

  • LRiG, The University of Liverpool

  • National Collaborating Centre for Cancer

  • National Institute for Health Research Health Technology Assessment Programme

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on ipilimumab by attending Committee discussions and providing written evidence to the Committee. They were also invited to comment on the ACD.

D Dr Paul Lorigan, Consultant Medical Oncologist, nominated by the organisation representing Skin Care Campaign, Factor 50, and Bristol-Myers Squibb – clinical specialist

  • Dr Paul Nathan, Consultant Medical Oncologist, nominated by the organisation representing Skin Care Campaign, and Factor 50 – clinical specialist

  • Mr Richard Jackson, nominated by the organisation representing Skin Care Campaign – patient expert

  • Ms Gillian Nuttall, CEO & Founder of Factor 50, nominated by the organisation representing Factor 50 – patient expert

E Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bristol Myers-Squibb Pharmaceuticals